4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD

About this update from 4d Molecular Therapeutics, Inc.

EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced enrollment completion for 4FRONT-2, the second Phase 3 clinical trial in our global program, evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD). "Completing global enrollment in both 4FRONT-1 and 4FRONT-2 Phase 3 trials with over-enrollment and ahead of initial projections further validates 4D-150 as the potential cornerstone of a transformative, category-defining retina franchise at 4DMT," said David Kirn, M.D., Co-founder, President and Chief Executive Officer of 4DMT. "The high enrollment rate across both 4FRONT-1 and 4FRONT-2 trials, predominantly in treatment-naïve patients, reflects the enthusiasm of patients and retina physicians for 4D-150, as well as the high unmet medical need for a vision-preserving durable backbone therapy in wet AMD. With two Phase 3 readouts expected in 2027 and initiation of a Phase 3 trial in diabetic macular edema in the third quarter of this year, we are rapidly advancing our vision of 4D-150 as the potential backbone therapy for patients with large-market retinal vascular diseases worldwide." "Wet AMD remains a leading cause of vision loss worldwide, and despite important advances in bolus anti-VEGF therapy, most patients still continue to face the real-world burden of frequent, lifelong injections and the associated risk of undertreatment and vision loss," said Julie Clark, M.D., Chief Medical Officer of 4DMT. "The completion of enrollment in 4FRONT-2 brings us one step closer to confirming the clinical evidence that 4D-150 can meaningfully reduce treatment burden while preserving vision outcomes. We are deeply grateful to the patients, investigators, study coordinators and sites around the world who have made this trial possible." "As retina specialists, we see every day how the need for frequent intravitreal injections can create an unsustainable burden for many patients, caregivers and practices, and how missed or delayed treatments frequently put vision at risk," said Patricio G. Schlottmann, M.D., Director of the Research Department at the Charles Ophthalmic Center...

View stock analysis, news, and events for 4d Molecular Therapeutics, Inc.